


**LISTING OF CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**IN THE CLAIMS:**

1. (Currently Amended) A compound of general formula (I) below:



wherein

each R group is, at one or more of the positions 4, 5, 6 and 7 of the indolinone ring and independently from each other, a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy group or a halogen atom;

each R<sub>1</sub> group is, the same or different and at one or more of the positions of the pyrrole ring, a C<sub>1</sub>-C<sub>4</sub> alkyl or a group of general formula -(CH<sub>2</sub>)<sub>p</sub>CO<sub>2</sub>R', -(CH<sub>2</sub>)<sub>p</sub>-CONR'R" or -CONH-(CH<sub>2</sub>)<sub>p</sub>-CONR'R" wherein p is 0, 1, 2 or 3, the alkylene -(CH<sub>2</sub>)<sub>p</sub>- chain is optionally substituted by hydroxy, and R' and R" are selected, each independently, from hydrogen or straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted by hydroxy or, taken together with the nitrogen atom to which they are attached, R' and R" may form a pyrrolidino, piperidino or morpholino group;

m is 0 or an integer from 1 to 4;

n is 0 or an integer from 1 to 3;


or pharmaceutically acceptable salts thereof.

2. (Original) A compound according to claim 1 wherein the pyrrole ring is substituted by one or more of the groups selected from methyl, carboxy, ethoxycarbonyl, carboxyethyl, N, N-diethyl-aminocarbonyl, N-[(2-diethylamino)ethyl]carboxamide or N-[2-hydroxy-3-morpholin-4-ylpropyl]carboxamide.


3. (Original) A compound according to claim 1 which is 3-[(3,5-dimethyl-1H-pyrrol-2-yl) [ $^{14}\text{C}$ ] methylene-1, 3-dihydro-2H-indol-2-one; 5-[1,2-dihydro-2-oxo-3H-indol-3-ylidene) [ $^{14}\text{C}$ ] methyl]-2, 4-dimethyl-1H-pyrrole-3-propionic acid; N-[(2-diethylamino)ethyl]-5-[(5-fluoro-1, 2-dihydro-2-oxo-3H-indol-3-ylidene) [ $^{14}\text{C}$ ] methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide; 3-{5-methyl-2-[(Z)-(2-oxo-1, 2-dihydro-3H-indol-3-ylidene) [ $^{14}\text{C}$ ] methyl]-1H-pyrrol-3-yl} propanoic acid; and 5-[(Z)-(5-fluoro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) [ $^{14}\text{C}$ ] methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide.

4. (Original) A process for preparing a compound of formula (I) according to claim 1 which process comprises:

a) reacting dimethyl-[ $^{14}\text{C}$ ] formamide with a suitable pyrrole derivative of formula (II), in the presence of diphosphoryl-chloride




wherein R<sub>1</sub> and n are as defined in claim 1, so as to obtain a compound of formula (III)



and optionally converting a compound of formula (III) into another compound of formula (III);



b) reacting under basic conditions the compound of formula (III) with an oxindole derivative of formula (IV)




wherein R and m are as defined in claim 1, so as to obtain a compound of formula (I) and, optionally converting it into another compound of formula (I) and/or into a pharmaceutically acceptable salt thereof.

5. (Original) A process according to claim 4 wherein, in step (b), basic conditions are obtained by means of pyrrolidine.

6. (Previously Presented) A compound of formula (IIIa) or (IIIb) below



wherein R<sub>1</sub> is a hydrogen atom or a group selected from -(CH<sub>2</sub>)<sub>2</sub>-CO<sub>2</sub>H, -CO<sub>2</sub>H, -CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CONH-(CH<sub>2</sub>)<sub>2</sub>-N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub> and



7. (Cancelled)